Contemporary Drug-Eluting Stent Platforms

Partida, Ramon A.; Yeh, Robert W.

doi:10.1016/j.ccl.2016.12.010

Cited by 10 publications

(13 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the biocompatibility of the polymers used for coating stents is of vital importance. As the polymer coating also acts as the eluting drug’s reservoir, it must be non-thrombogenic, non-inflammatory, non-toxic to cells, and should encourage arterial healing by re-endothelialization [ 12 , 19 , 21 , 23 , 63 ]. In this respect, the adequate features of phosphorylcholine, polylactic acid, poly(vinylidencefluoride-co-hexafluoropropenen), and polyvinylpyrrolidone have attracted interest for stent coatings, mitigating inflammation and thrombosis risk [ 6 , 24 , 64 ].…”

Section: Evolution Of Cardiovascular Stentsmentioning

confidence: 99%

“…Regarding the incorporated drugs, new substances have been proposed in these stents, such as zotarolimus, everolimus, and novolimus [ 6 , 68 , 69 , 70 , 71 , 72 ]. Through their diffusion into the vessel wall, these compounds lead to good endothelial coverage, inhibition of vascular restenosis, and suppression of transplant rejection [ 20 , 22 , 52 , 63 ]. Moreover, drug diffusivity is highly dependent on the size and charge of the drug.…”

Section: Evolution Of Cardiovascular Stentsmentioning

confidence: 99%

“…Other materials were proposed for the metallic platform, namely cobalt-chromium and platinum-chromium alloys, as they allowed a reduction in the strut thickness [6]. The extra benefits that the new platform alloys brought were superior radial force and better radiopacity, with thinner strut formulations than the 316L stainless steel used in previous stent generations [12,23,63]. DESs were mainly adopted as a solution for in-stent restenosis, a major problem associated with the stenting procedure [52].…”

Section: Drug-eluting Stentsmentioning

confidence: 99%

See 2 more Smart Citations

Cardiovascular Stents: A Review of Past, Current, and Emerging Devices

et al. 2021

View full text Add to dashboard Cite

One of the leading causes of morbidity and mortality worldwide is coronary artery disease, a condition characterized by the narrowing of the artery due to plaque deposits. The standard of care for treating this disease is the introduction of a stent at the lesion site. This life-saving tubular device ensures vessel support, keeping the blood-flow path open so that the cardiac muscle receives its vital nutrients and oxygen supply. Several generations of stents have been iteratively developed towards improving patient outcomes and diminishing adverse side effects following the implanting procedure. Moving from bare-metal stents to drug-eluting stents, and recently reaching bioresorbable stents, this research field is under continuous development. To keep up with how stent technology has advanced in the past few decades, this paper reviews the evolution of these devices, focusing on how they can be further optimized towards creating an ideal vascular scaffold.

show abstract

Section: Evolution Of Cardiovascular Stentsmentioning

confidence: 99%

Section: Evolution Of Cardiovascular Stentsmentioning

confidence: 99%

Section: Drug-eluting Stentsmentioning

confidence: 99%

See 1 more Smart Citation

Cardiovascular Stents: A Review of Past, Current, and Emerging Devices

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Paclitaxel, Sirolimus and Sirolimus-derived) are encapsulated in the metal backbone of the stent by linking them on the implant's surface, by using carrier, or by embedding the device in a durable polymeric materials, that acted as reservoir [65]. The used drugs can be classified as immunosuppressive, antiproliferative, anti-inflammatory, antithrombotic and pro-healing agents [72,65,73].…”

Section: Cvd Current Approachesmentioning

confidence: 99%

“…lung, breast and ovarian cancer) and used in this case to prevent instent restenosis [74]. Particularly, it inhibits muscle cells proliferation [73]. Sirolimus, is an antibiotic with anti-proliferative and anti-inflammatory properties, very similar to Paclitaxel and both inhibit smooth muscle cell proliferation, but with very different mechanism of action as they block the mitosis at two different stages [65,72].…”

Section: Cvd Current Approachesmentioning

confidence: 99%

Long-acting implantable devices for the prevention and personalised treatment of infectious, inflammatory and chronic diseases

Corduas

Mancuso

Lamprou

2020

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

show abstract

Impact of stent designs of second‐generation drug‐eluting stents on long‐term outcomes in coronary bifurcation lesions

Jang

Chun

Park

et al. 2020

Cathet Cardio Intervent

View full text Add to dashboard Cite

Objectives: We compared the long-term clinical outcomes of four different types of second-generation drug-eluting stents (DESs) in coronary bifurcation lesions. Background: Clinical outcomes of different designs of second-generation DESs are not well known in bifurcation lesions. Methods: Patients who underwent percutaneous coronary intervention with secondgeneration DESs for coronary bifurcation lesion were enrolled from 21 centers in South Korea. A total of 2,526 patients was evaluated and divided into four treatment groups according to DES type: bioabsorbable polymer biolimus-eluting stent (BP-BES group, n = 514), platinum chromium everolimus-eluting stent (PtCr-EES group, n = 473), cobalt nickel zotarolimus-eluting stent (CoNi-ZES group, n = 736), or cobalt chromium everolimus-eluting stent (CoCr-EES group, n = 803). Primary outcome was target lesion failure (TLF, defined as a composite of cardiac death, target vessel myocardial infarction, or target lesion revascularization). Inverse probability of treatment weighting (IPTW) was performed to reduce selection bias and potential confounding factors.Results: For 5 years of follow-up, the rates of TLF among the four DES groups were not significantly different (6.2% for BP-BES group, 8.2% for PtCr-EES group, 6.5% for CoNi-ZES group, and 8.6% for CoCr-EES group, p = .434). The results were consistent after IPTW adjustment (6.8, 8.4, 6.0, and 7.5%, respectively, p = .554). In subgroup analysis, the similarity of long-term outcomes among the four different types of second-generation DES was consistent across subgroups regardless of side branch treatment (p for interaction = .691). Conclusion:There seems to be no significant difference in long-term clinical outcomes among patients who received different types of second-generation DES for coronary bifurcation lesion.Woo Jin Jang and Woo Jung Chun contributed equally to this study.

show abstract

Contemporary Drug-Eluting Stent Platforms

Cited by 10 publications

References 98 publications

Cardiovascular Stents: A Review of Past, Current, and Emerging Devices

Cardiovascular Stents: A Review of Past, Current, and Emerging Devices

Long-acting implantable devices for the prevention and personalised treatment of infectious, inflammatory and chronic diseases

Impact of stent designs of second‐generation drug‐eluting stents on long‐term outcomes in coronary bifurcation lesions

Contact Info

Product

Resources

About